TELA Bio (TELA) Q2 2024 earnings summary

Executive summary

• Revenue grew 11% year-over-year to $16.1 million in Q2 2024, driven by new customers, increased penetration, and expanded commercial reach, despite transient challenges such as ransomware attacks and lower procedure volumes.

• Net loss for Q2 2024 was $12.6 million, up from $10.8 million in Q2 2023, primarily due to increased operating expenses.

• The company expects a strong recovery in the second half of 2024, supported by July sales trends, ongoing commercial initiatives, and normalization after cyberattack disruptions.

• New product launches, including LiquiFix and OviTex IHR, are receiving positive feedback and are expected to drive further market penetration, especially in minimally invasive and robotic hernia repair.

• Appointment of Greg Firestone as Chief Commercial Officer aims to enhance sales force effectiveness and operational efficiency.

Financial highlights

• Q2 2024 revenue: $16.1 million, up 11% year-over-year; gross margin: 69% (down from 70% in Q2 2023) due to higher inventory charges.

• Net loss was $12.6 million in Q2 2024; loss per share was $0.51.

• Operating expenses increased to $22.6 million, mainly from higher sales, marketing, and headcount costs.

• Cash and cash equivalents at June 30, 2024, totaled $26.5 million; working capital was $36.1 million.

• For the six months ended June 30, 2024, revenue was $32.7 million (up 24% year-over-year), and net loss was $18.3 million, aided by a $7.6 million gain on the sale of the NIVIS product line.

Outlook and guidance

• Full-year 2024 revenue guidance maintained at $74.5–$76.5 million, representing 27–31% growth over 2023.

• Management expects normalized growth in Q3 and a stronger Q4 as new commercial initiatives ramp and market disruptions subside.

• Operating and net losses are expected to decline sequentially through 2024, with lower cash consumption in the second half.

• Revenue share payments from the NIVIS divestiture to begin in Q3, totaling $3–$7 million over eight quarters.

• Existing cash resources are expected to fund operations for at least the next 12 months.